Irbesartan for Hypertension in Metabolic Syndrome Patients
Author Information
Author(s): Kintscher Ulrich, Bramlage Peter, Paar W Dieter, Thoenes Martin, Unger Thomas
Primary Institution: Center for Cardiovascular Research (CCR), Institute of Pharmacology, Charité, Berlin, Germany
Hypothesis
Does Irbesartan improve blood pressure and metabolic risk factors in patients with metabolic syndrome?
Conclusion
Irbesartan treatment significantly improved blood pressure and metabolic risk factors in patients with metabolic syndrome.
Supporting Evidence
- Irbesartan monotherapy resulted in a significant reduction of blood pressure.
- Patients with metabolic syndrome showed improvements in HDL cholesterol, triglycerides, and fasting blood glucose.
- Combination therapy with hydrochlorothiazide did not adversely affect metabolic control.
Takeaway
This study shows that a medicine called Irbesartan helps lower blood pressure and makes people healthier when they have a condition called metabolic syndrome.
Methodology
A multicenter, prospective, two-armed, observational study over 9 months involving 14,200 patients with uncontrolled hypertension.
Potential Biases
Potential biases due to non-randomized patient selection.
Limitations
The study was not controlled, and the influence of unknown biases cannot be assessed.
Participant Demographics
Patients included both men and women, with a mean age of 61.2 years for those without metabolic syndrome and 62.4 years for those with it.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website